Vallerie McLaughlin
Kim A Eagle M.D. Endowed Professor of Cardiovascular Medicine
Program Associate
Internal Medicine
Professor of Internal Medicine
Medical School
Michigan Medicine
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
[email protected]
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
Available to mentor
Vallerie McLaughlin
Professor
Manage Your Profile
Qualifications
-
MDNorthwestern University Medical School, Evanston, IL, United States
1985 - 1989
-
BSNorthwestern University, Evanston, IL, United States
1981 - 1985
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Research Overview
1. Pulmonary Hypertension
2. Pulmonary vascular disease
Recent Publications
-
Mclaughlin VV, Ataya A, Barbera JA, Benza RL, Meyer GB, Chang S, Channick RN, Feenstra JF, Gaine SP, Giannakoulas G, Diaz CS, Khanna D, Kim NH, Lachant DJ, Oudiz RJ, Preston IR, Sood N, Torres F, Vachiery JE, Zamudio TP, Cella D, Escudero M, Lacasse V, Solum DT, Humbert MJ. American Journal of Respiratory and Critical Care Medicine, 2026 Jun 24; 212 (Supplement_2): aamag286.300Journal ArticleD28-20 ADVANCE Outcomes: A Phase 3, Randomized Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension
DOI:10.1093/ajrccm/aamag286.300 -
Gomberg-Maitland M, Ghofrani HA, Gibbs JSR, Hoeper MM, Humbert M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Miller B, Lin J, Shi Y, Perchenet L, Strait J, Cornell AG, Badesch DB. Chest, 2026 May 27;Journal ArticleSotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.
DOI:10.1016/j.chest.2026.04.056 PMID: 42208730 -
Osterhout R, Boucly A, Benza RL, Channick RN, Chin KM, Frantz RP, Hemnes AR, Howard LS, Mclaughlin VV, Sitbon O, Vachiéry J-L, Zamanian RT, Aranda R, Cravets M, Ding Z, Duong-Verlé T, Mottola D, Roscigno RF, Sitapara R, Zisman LS, Bruey J-M, Ghofrani H-A. Am J Respir Crit Care Med, 2026 May 8;Journal ArticleCirculating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
DOI:10.1093/ajrccm/aamag175 PMID: 42104009 -
Souza R, Badesch DB, Ghofrani HA, Gibbs S, Gomberg-Maitland M, Hoeper M, Humbert M, Preston IR, Waxman AB, Grünig E, Hassoun P, Highland KB, Mathai SC, Miller B, Lin J, Shi Y, Brambatti M, Loureiro M, Cornell AG, Mackenzie HS, Perchenet L, Dezia A, Mclaughlin VV. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.5479Journal ArticleA19-03 Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue Disease (CTD): A Pooled Analysis From STELLAR, ZENITH, and HYPERION
DOI:10.1093/ajrccm/aamag162.5479 -
Mclaughlin VV, Badesch DB, Ghofrani HA, Gibbs S, Gomberg-Maitland M, Hoeper M, Preston IR, Souza R, Waxman AB, Grünig E, Kopéc G, Olsson KM, Shi Y, Miller B, Lin J, Martinez EC, Brambatti M, Humbert M. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.5481Journal ArticleA19-05 Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension Receiving Double-background Therapy: A Pooled Analysis From PULSAR, STELLAR, ZENITH, and HYPERION
DOI:10.1093/ajrccm/aamag162.5481 -
Humbert MJ, Backer A, Boyanova N, Hoeper MM, Kracker H, Lack G, Mclaughlin VV, Preston I, Tamura Y. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.5571Journal ArticleA65-09 UNISUS Hemodynamic Sub-study: Study Design and Patient Characteristics from the First Head-to-head Superiority Study in Pulmonary Arterial Hypertension (PAH)
DOI:10.1093/ajrccm/aamag162.5571 -
Gomberg-Maitland M, Ghofrani HA, Gibbs S, Hoeper M, Humbert M, Mclaughlin VV, Preston IR, Souza R, Waxman AB, Miller B, Liu C, Shi Y, Perchenet L, Cornell AG, Badesch DB. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.5736Journal ArticleB106-05 Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Classified as Intermediate-low Risk: A Pooled Analysis From PULSAR, STELLAR, and HYPERION
DOI:10.1093/ajrccm/aamag162.5736 -
Preston IR, Boyanova N, Csonka D, Humbert M, Kracker H, Mclaughlin VV, Tamura Y, Hoeper MM. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.5831Journal ArticleC64-14 Pharmacokinetic/Pharmacodynamic (PK/PD) Sub-study of UNISUS in Pulmonary Arterial Hypertension (PAH): Characteristics of Enrolled Patients
DOI:10.1093/ajrccm/aamag162.5831
Featured News & Stories
Health Lab
Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine by Michigan Medicine.
